chevron_leftBack
As of 5 June 2026, Psyence Group Inc. has a market cap of $1.35M USD, ranking #47995 globally and #2602 in Canada.
It ranks #4257 in the Healthcare sector, and #1347 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.35MUSD
1.88M CAD
Enterprise Value
$771.81KUSD
1.07M CAD
EBITDA (TTM)
-$1.49MUSD
-2.08M CAD
Net Income (TTM)
-$789.61KUSD
-1.1M CAD
PB Ratio
2.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Founded
2019
Website
psyence.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 9.1% | -14% | -23% | -27% | -20% | -60% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PSYG
Psyence Group Inc Ordinary Shares
ISIN: CA74449Q2053
Shares Out.:
Shares Outstanding:
15.638M1
Shares Float:
15.22M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1200 CAD | |
|
PSYGF
Psyence Group Inc Ordinary Shares
ISIN: CA74449Q1063
Shares Out.:
Shares Outstanding:
140.451M1
Shares Float:
133.583M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1165 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. It also focuses on the research and development, cultivation, and production of psilocybin mushrooms and functional over-the-counter mushroom products. The company offers its functional mushroom products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: XENE
|
$5.39B
399K%
|
-
|
|
TSX: GUD
|
$521.69M
39K%
725.1M CAD
|
-
|
|
NASDAQ: MIST
|
$223.22M
16K%
|
-
|
|
TSX: MSCL
|
$156.02M
11K%
216.85M CAD
|
-
|
|
TSXV: RX
|
$119.33M
9K%
165.86M CAD
|
18.5
|
|
TSX: HBP
|
$111.0M
8K%
154.28M CAD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
56M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
41M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
27M%
|
97.4
|
|
SIX: RO
|
$324.68B
24M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
21M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
21M%
218.9B CHF
|
20.5
|
chevron_leftBack